Return to homepagePandemic Pact

Neutralizing Antibodies as SARS-CoV-2 Therapeutics [Added supplement: COVID-19 Variant Supplement]

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:0 publications

Grant number: 170649, 175552

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2022

  • Known Financial Commitments (USD)

    $414,222.6

  • Funder

    Canadian Institutes of Health Research (CIHR)

  • Principal Investigator

    James M Rini

  • Research Location

    Canada

  • Lead Research Institution

    University of Toronto

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Three highly virulent coronaviruses - SARS-CoV, MERS-CoV and SARS-CoV-2 - have crossed species barriers to infect humans since 2003. SARS-CoV-2 is responsible for COVID-19, a disease that arose in Wuhan China in December of 2019. The virus has infected over 64,000 people and caused 1380 deaths and the World Health Organization has declared it a public health emergency of international concern. Although drastic measures are being taken to contain SARS-CoV-2, there is an urgent need for new therapeutics to combat this virus and reduce its spread. In this work we will develop therapeutics based on human antibodies that can be used in the treatment of COVID-19.